

RESEARCH ARTICLE

A unique stylopod patterning mechanism by *Shox2*-controlled osteogenesis

Wenduo Ye^{1,*}, Yingnan Song^{1,2,*}, Zhen Huang^{1,2}, Marco Osterwalder³, Anja Ljubojevic⁴, Jue Xu^{1,5}, Brent Bobick⁴, Samuel Abassah-Oppong⁴, Ningsheng Ruan^{1,2}, Ross Shamby¹, Diankun Yu¹, Lu Zhang⁶, Chen-Leng Cai⁶, Axel Visel^{3,7,8}, Yanding Zhang², John Cobb⁴ and YiPing Chen^{1,2,†}

ABSTRACT

Vertebrate appendage patterning is programmed by Hox-TALE factor-bound regulatory elements. However, it remains unclear which cell lineages are commissioned by Hox-TALE factors to generate regional specific patterns and whether other Hox-TALE co-factors exist. In this study, we investigated the transcriptional mechanisms controlled by the *Shox2* transcriptional regulator in limb patterning. Harnessing an osteogenic lineage-specific *Shox2* inactivation approach we show that despite widespread *Shox2* expression in multiple cell lineages, lack of the stylopod observed upon *Shox2* deficiency is a specific result of *Shox2* loss of function in the osteogenic lineage. ChIP-Seq revealed robust interaction of *Shox2* with cis-regulatory enhancers clustering around skeletogenic genes that are also bound by Hox-TALE factors, supporting a lineage autonomous function of *Shox2* in osteogenic lineage fate determination and skeleton patterning. Pbx ChIP-Seq further allowed the genome-wide identification of cis-regulatory modules exhibiting co-occupancy of Pbx, Meis and *Shox2* transcriptional regulators. Integrative analysis of ChIP-Seq and RNA-Seq data and transgenic enhancer assays indicate that *Shox2* patterns the stylopod as a repressor via interaction with enhancers active in the proximal limb mesenchyme and antagonizes the repressive function of TALE factors in osteogenesis.

KEY WORDS: Limb, Patterning, *Shox2*, Skeleton, Stylopod

INTRODUCTION

The body segments and appendages of vertebrates are patterned by clusters of Hox and paraHox genes that are expressed along the major body axes (Pearson et al., 2005). Mutations or even subtle changes in the expression of Hox genes cause homeotic transformation of the axial skeleton (Kondrashov et al., 2011; Pearson et al., 2005), and reduction or loss of skeletal elements in vertebrate limbs (Kondrashov et al., 2011; Zakany and Duboule, 2007). In contrast

to the specific *in vivo* requirement of Hox gene expression for correct patterning, the *in vitro* binding specificity of Hox factors to DNA motifs remains controversial, raising the question whether additional machineries such as transcription co-factors exist to ensure the regional specific function of Hox genes (Mann et al., 2009). Indeed, a family of three amino acids loop extension (TALE) homeodomain proteins including Meis and Pbx subclasses has been extensively characterized as DNA binding co-factors for Hox proteins to achieve the DNA binding specificity and form a highly conserved Hox-TALE patterning system with its origin being traced back to ancestral species such as starlet sea anemone (Hudry et al., 2014; Mann et al., 2009; Parker et al., 2011; Slattery et al., 2011). However, it is still under debate whether TALE factors could fully satisfy the *in vivo* binding specificity of Hox proteins. The recently proposed low-affinity Hox-TALE binding motif clusters on Hox-TALE bound enhancers (Crocker et al., 2015) implies the existence of additional factors to confer sufficient *in vivo* binding specificity. Alternatively, instead of being the primary binding factor, Hox proteins are known to play an accessory role for the interaction of Meis transcription factors with specific enhancers. Moreover, Meis factors can even function without Hox on a large proportion of these enhancers in branchial arch (BA) patterning (Amin et al., 2015), suggesting that additional tissue-specific transcriptional mechanisms contribute to the *in vivo* binding specificity of enhancers with Hox and TALE factors. However, whether other co-factors exist for Hox-TALE system so far remains unknown.

In the developing vertebrate limb, bone elements form via endochondral ossification, whereas osteogenesis is preceded by the formation of cartilaginous template with *Runx2*⁺/*Osx*⁺ osteogenic precursors initially residing in the perichondrium and later on invading into cartilaginous template (Long and Ornitz, 2013). Limb skeletal patterning by Hox-TALE transcriptional complexes was proposed to be essential for endochondral skeletogenesis by directly regulating cartilage template formation (Zakany and Duboule, 2007). Along the proximal to distal (PD) axis, the skeletal elements of tetrapod limbs are patterned by *Hox9* to *Hox13* located within the HoxA/D gene clusters. Additionally, the expression of TALE factors is also regulated by signaling pathways along the PD axis, in which context the proximal retinoic acid (RA) signaling and the distal FGF signaling antagonistically determine the proximal expression of Meis genes that marks the stylopodial segment and facilitates the nuclear localization of Pbx in the proximal limb (Cunningham and Duester, 2015; Mercader et al., 2000). Together with HoxA/D9 and HoxA/D10, Meis and Pbx provides patterning code for the stylopodial skeleton (Capellini et al., 2011; Cunningham and Duester, 2015; Penkov et al., 2013). Intriguingly, compound deletion of HoxA/D gene clusters produces considerably milder defects in the stylopodial skeleton than that in the distal zeugopodial and autopodial skeletons that are

¹Department of Cell and Molecular Biology, Tulane University, New Orleans, LA 70118, USA. ²Southern Center for Biomedical Research and Fujian Key Laboratory of Developmental and Neural Biology, College of Life Sciences, Fujian Normal University, Fuzhou, Fujian 350108, People's Republic of China. ³Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA. ⁴Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada T2N 1N4. ⁵State Key Laboratory of Oral Disease, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China. ⁶Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ⁷U.S. Department of Energy Joint Genome Institute, Walnut Creek, CA 94598, USA. ⁸School of Natural Sciences, University of California at Merced, Merced, CA 95343, USA.

*These authors contributed equally to this work

†Author for correspondence (ychen@tulane.edu)

© Y.P.C., 0000-0002-8628-7713

patterned by *Hox10-Hox13* (Kmita et al., 2005; Raines et al., 2015), suggesting that the stylopod adopts a unique mechanism for patterning that is less dependent on *HoxA/D* factors.

We have shown previously that inactivation of *Shox2*, encoding a paired-like homeodomain transcription factor, causes developmental defects of multiple organs including the heart, palate and limb (Bobick and Cobb, 2012; Cobb et al., 2006; Espinoza-Lewis et al., 2009; Ye et al., 2015a; Yu et al., 2005, 2007). Strikingly, *Shox2* mutation causes loss of the stylopod in both forelimbs and hindlimbs, which was thought to be attributed to the direct function of *Shox2* in chondrogenesis (Bobick and Cobb, 2012; Yu et al., 2007). However, an epistatic additive interaction between *HoxA/D* genes and *Shox2* was seen in limb development (Neufeld et al., 2014), suggesting an involvement of *Shox2* in the *Hox*-TALE patterning system.

Here, using our unique *Shox2* allelic toolsets, we undertook a comprehensive analysis of *Shox2* expression and the fate of *Shox2*⁺ cells in the developing limb. Hereby, we reveal an unexpected direct role of *Shox2* in osteogenesis for stylopodial skeletal patterning. Our ChIP-Seq and RNA-Seq analyses demonstrate that *Shox2* functions by directly regulating enhancers that are co-occupied by *Hox*-TALE factors to specify the stylopod that emerges in the juxtaposition of the trunk with strong *Meis* and *Pbx* gene expression and the proximal limb where *Shox2* is highly expressed. Moreover, by retrospective and *de novo* characterization of *Shox2*-occupied enhancers, we demonstrate that co-occupancy of *Shox2* and TALE factors represents a key feature of the enhancer grammar for proximal limb-specific enhancer activity. Our results indicate that *Shox2* acts as a repressor on these enhancers and is required for modulation of cell fate choices in limb development.

RESULTS

Shox2 is expressed in mesenchymal progenitors of multiple cell types in the proximal limb

We have shown previously that *Shox2* is expressed in the developing proximal limb and *Shox2* deficiency causes severely mispatterned stylopodial skeletal elements (Cobb et al., 2006; Yu

et al., 2007). To unravel the functional mechanism of *Shox2* in stylopod patterning, we first sought to comprehensively document and analyze *Shox2* expression patterns and cell populations that are derived from *Shox2*⁺ cells. We took advantage of our recently generated *Shox2*^{HA/+} (Wang et al., 2014; Ye et al., 2015b) and *Shox2*^{Cre/+} (Sun et al., 2013) alleles for protein expression analysis and fate mapping.

The *Shox2*^{HA/+} allele represents a knock-in of a *Flag-2xHA-Shox2a-IRES-DsRed-pA* coding cassette into the endogenous *Shox2* locus (Wang et al., 2014; Ye et al., 2015a), which allows live imaging of *Shox2* expression via DsRed and *Shox2* protein localization using anti-HA antibodies. We chose to analyze *Shox2* expression starting from embryonic day (E)12.5 at which stage the distinct anlagen of stylopodial and zeugopodial skeletal elements are formed. Live imaging revealed strong *Shox2* expression in the proximal portion of the developing limb at E12.5 (Fig. 1A,B). An intensive *Shox2* expression in the proximal limb, especially around the chondrogenic center of the stylopod, was observed by anti-HA staining at the same stage (Fig. 1C). Consistent with broad *Shox2* expression at E12.5, fate mapping using *Shox2*^{Cre/+} allele revealed contribution of *Shox2*⁺ cells to multiple connective tissue cell types, including chondrocytes, osteoblasts, adipocytes, and dermal fibroblasts (Fig. 1D–G). In contrast to the extensive labeling of osteogenic cells in the bone-forming area (Fig. 1E), *Shox2*^{Cre/+} labeled only a portion of chondrocytes (Fig. 1D), consistent with relatively weak real-time *Shox2* expression in the chondrogenic center (Fig. 1C).

Deletion of *Shox2* results in specific loss of *Shox2*⁺/*Runx2*⁺ perichondrial cells

As the expression analysis and fate-mapping results did not indicate a lineage etiology for the phenotype observed in *Shox2* mutants and *Shox2*-expressing cells contribute extensively to the proximal connective tissue cells, we speculated that virtual loss of the stylopod in *Shox2* mutants results from absence of *Shox2*⁺ cells. We therefore compounded the *Rosa*^{mTmG} allele to *Shox2*^{Cre/+} mice (null mutant) to examine the contribution of *Shox2*⁺ cells in the absence of *Shox2*.




Fig. 1. *Shox2* is expressed in mesenchymal progenitors of multiple cell types in the proximal limb. (A,B) Live imaging on *Shox2*^{HA/+} embryo reveals proximal expression of *Shox2* (arrowhead) in embryonic forelimb (A) and hindlimb (B) at E12.5. (C) Immunofluorescence using anti-HA antibody on *Shox2*^{HA/+} embryo reveals strong perichondrial expression of *Shox2* (arrowhead). (D–G) MF20 and GFP immunofluorescence on *Shox2*^{Cre/+}; *Rosa*^{mTmG} embryonic (D) and postnatal (E) mice reveals broad contribution of *Shox2*⁺ cells to connective tissue cell types such as chondrocyte (arrowheads in D), osteoblast/osteocyte (arrowheads in F) and dermal fibroblast (arrowhead in G). H, humerus; R, radius; U, ulna; F, femur.

Shox2^{Cre/+}; *Rosa*^{mTmG} mice were analyzed at E13.0, the latest stage the *Shox2* deficient embryos appear normal prior to severe complications caused by cardiac defects (Espinoza-Lewis et al., 2009; Ye et al., 2015b). In these embryos, the *Shox2*⁺ lineage is labeled by mGFP, and the expression pattern of mGFP reporter did not change significantly compared with controls (Fig. 2), indicating that *Shox2* is not required for the proliferation and migration of the majority of *Shox2*⁺ cells in the stylopod. Consistent with the weak and transient expression of *Shox2* in the chondrocytes of controls (Fig. 2A–C), the chondrogenic center of the stylopodial skeleton formed in *Shox2*-deficient *Shox2*^{Cre/+}; *Rosa*^{mTmG} embryos (Fig. 2D–F). Interestingly, intensive *Shox2* expression in the perichondrium of the stylopod of control embryos was observed at this stage (Fig. 2A). Immunostaining on the adjacent sections showed that these cells are also positive for Runx2, a molecular marker for osteoblastic precursors (Fig. 2C). However, in *Shox2*^{Cre/+}; *Rosa*^{mTmG} embryos, these *Shox2*⁺/*Runx2*⁺ cells lost *Runx2* expression completely and expressed *Sox9* aberrantly, indicating defective fate decision (Fig. 2B,C,E,F).

***Shox2* inactivation in osteogenic lineage precursors recapitulates limb defects in *Shox2*-null mutants**

Given a potential role of the embryonic perichondrium as the osteogenic precursor pool (Colnot et al., 2004) and the extensive contribution of *Shox2*⁺ cells to osteoblasts/osteocytes (Fig. 1E), we

asked whether *Shox2*⁺ osteogenic cells are derived from *Shox2*⁺/*Runx2*⁺ perichondrial cells and if the defective fate decision of early perichondrial *Shox2*⁺/*Runx2*⁺ cells could lead to aberrant osteogenic differentiation of *Shox2*⁺ cells at a later stage. To overcome the cardiac pacemaker defects that cause early embryonic lethality in *Shox2* mutants, we made use of *Nkx2-5*^{F/F} allele that, in combination with the *Shox2*^{Cre/+}; *Rosa*^{mTmG} alleles, conditionally rescues the cardiac defects and allows *Shox2* mutants to survive to the birth without interfering defects in other organs irrelevant to *Nkx2-5* (our unpublished results).

At E14.0, GFP⁺/Osterix⁺ cells could be clearly detected in the inner layer of perichondrium in the stylopod of *Shox2*^{Cre/+}; *Nkx2-5*^{F/F}; *Rosa*^{mTmG} embryos (Fig. 3A). At E17.5, the GFP⁺/Osterix⁺ osteoblast/osteocytes were abundantly localized in the diaphysis of the stylopodial skeleton (Fig. 3B). Together with the restricted *Shox2* expression in the perichondrium at E14.5 (Fig. 3E–H) and the complete lack of *Shox2* expression in the stylopodial skeleton at E17.5 (data not shown), our observations indicate a direct contribution of the *Shox2*⁺ perichondrial cells to the osteogenic lineage. However, in *Shox2*-deficient embryos (*Shox2*^{Cre/+}; *Nkx2-5*^{F/F}; *Rosa*^{mTmG}) at E14.0 and E17.5, the Osterix⁺ layer of perichondrial cells and the GFP⁺/Osterix⁺ osteogenic cells that were otherwise found abundantly in the diaphysis of control mice, were absent (Fig. 3C,D). The requirement of *Shox2* for the formation of osteogenic cells appears to occur at the early fate




Fig. 2. Deletion of *Shox2* results in specific loss of *Shox2*⁺/*Runx2*⁺ perichondrial cells. (A–F), Co-immunofluorescence of *Shox2*, mGFP, *Sox9* and *Runx2* in the forelimb of *Shox2*^{Cre/+}; *Rosa*^{mTmG} embryos at E13.0 (D–F) compared with littermate *Shox2*^{Cre/+}; *Rosa*^{mTmG} mice (A–C) shows loss of distinct stylopodial perichondrial structure (arrowheads) in the absence of *Shox2* compared with that of zeugopod (arrow in F). Humerus regions are magnified in inserts A', A'', B', B'', C', C'', E', E'', F', F''. H, humerus; R, radius.




Fig. 3. *Shox2* inactivation in osteogenic lineage recapitulates limb defects in *Shox2*^{-/-} mice. (A–D) Co-immunofluorescence of *Osx* and GFP shows the absence of osteogenic cells (arrowheads) in the humerus of *Shox2*^{Cre/+};*Nkx2-5*^{F/F};*Rosa*^{mTmG} mice at E14.0 (C) and E17.5 (D) in comparison to littermate control *Shox2*^{Cre/+};*Nkx2-5*^{F/F};*Rosa*^{mTmG} mice (A,B). (E–H) Co-immunofluorescence on E14.5 *Shox2*^{HA/+} embryo shows restricted expression of *Shox2* in the outer layer (arrowheads) of the perichondrium and strong *Runx2* expression in the inner layer (arrows). (I) GFP staining shows specific osteogenic activation (arrowheads) by *Col3.6-Cre* in a *Col3.6-Cre*;*Rosa*^{mTmG} embryo at E17.5. (J) Alcian Blue/Alizarin Red staining on a representative *Col3.6-Cre*;*Rosa*^{mTmG} mouse in comparison to its littermate control at P0. Red arrows indicate stylopodial skeleton. (K,L) Alcian Blue/Alizarin Red staining shows specific stylopodial defect (arrowheads) in *Col3.6-Cre*;*Shox2*^{F/F} mice similar to that of *Shox2*^{-/-} mice, compared with the *Col2a1-Cre*;*Shox2*^{F/F} mice (L) and WT mice at P0 (the littermate control for *Col2a1-Cre*;*Shox2*^{F/F} mice at P0 is shown in L). H, humerus.

determination phase. This is supported by the observations that at E14.5, *Shox2* expression becomes predominantly restricted to the outer layer of the perichondrium that is characterized by relatively low levels of *Runx2* expression (Fig. 3E–H) and was thought to have a less definitive role in osteogenesis (Swinehart et al., 2013).

It was proposed that skeletal patterning in the limb by *Hox* genes is largely exerted by their expression in the perichondrium (Swinehart et al., 2013; Villavicencio-Lorini et al., 2010). Given that *Shox2* deficiency causes a specific loss of perichondrial osteogenic cell type signature and leads to a depletion of osteogenic cells, we hypothesized that *Shox2* functions to control stylopodial skeleton patterning through maintaining the fate of perichondrial

osteogenic precursors that initially provide instructive cues for chondrocyte differentiation, and later differentiate to osteoblasts for bone formation. In supporting this hypothesis, we found that *Shox2*⁺ cells contribute specifically to the osteogenic population of the stylopodial skeleton but not that of the zeugopodial skeletal elements (Fig. S1), correlating well with the specific loss of the stylopod in *Shox2* mutants.

To determine if *Shox2* expression in the osteogenic cells is essential for stylopod patterning, we utilized *Col3.6-Cre* (Liu et al., 2004) to inactivate *Shox2* specifically in osteogenic cells (Fig. 3I). In *Col3.6-Cre*;*Shox2*^{F/F} mice, the stylopodial elements of both forelimb and hindlimb were severely shortened (Fig. 3J), mimicking

the limb defects observed in *Shox2*-null mutants (Fig. 3K). Together with the fact that cartilage-specific deletion of *Shox2* by *Col2a1-Cre* did not produce a similar limb phenotype (Fig. 3K; Fig. S1), our results demonstrate a pivotal role for *Shox2* in the osteogenic lineage essential for stylopodial skeleton patterning.

Shox2 binds predominantly to limb-specific distal enhancers involved in skeletogenesis

To reveal the regulatory molecular framework behind this unique *Shox2* function in osteogenic differentiation in the stylopod, we used the *Shox2*^{HA} allele that allows efficient immunoprecipitation of endogenous HA-tagged *Shox2* (Fig. 4A). We performed anti-HA ChIP-Seq using developing limbs from *Shox2*^{HA/+} and wild-type control embryos at E12.5 and E13.5. Resulting peaks with various levels of fold enrichment were successfully verified by ChIP-qPCR (Fig. S2).

We first assigned the *Shox2* binding peaks to the nearby coding genes and assessed the gene ontology (GO). The GO terms for skeletogenesis are highly enriched for nearby genes flanking *Shox2* binding peaks, indicating a pivotal role of *Shox2* in osteogenesis despite its broad expression in progenitor cells of multiple connective tissue cell types (Fig. 4B). Our analysis showed that *Shox2* interacts predominantly with distal regulatory elements that are highly conserved among vertebrates as shown by plotting based on PhastCons (Fig. 4C). We next plotted *Shox2* binding signals with the DNaseI hypersensitivity sequencing (DHS) data generated by the Encode project (Yue et al., 2014). *Shox2* binding signals and DHS signals from the developing limb (E11.5), and adult heart and lung were categorized based on relative signal intensity using k-mean clustering into four groups. As shown in Fig. 4D, the genome-wide binding intensity of *Shox2* at E12.5 and E13.5 is generally similar, suggesting a persistent function of *Shox2*. Moreover, the majority of *Shox2* binding sites colocalize with DHS sites accessible specifically in the embryonic limb, which are enriched for skeletogenic-related GO terms (Fig. S3). Therefore, our identified limb-specific *Shox2* target regions likely contain the unique set of *Shox2*-controlled cis-regulatory modules that is required for the transcriptional control of skeletal patterning genes in the stylopod.

To further characterize if these *Shox2*-bound elements represent active enhancers, we plotted the published histone modifications H3K4me1, H3K27ac and H3K27me3 ChIP-Seq data obtained from embryonic limbs (Attanasio et al., 2014) versus the *Shox2* binding peak summits. Indeed, the active enhancer markers H3K4me1 and H3K27ac are generally enriched around *Shox2* binding sites (Fig. 4E). In addition, H3K27me3, which is frequently associated with inactive enhancers, appears to be mildly enriched around summits of *Shox2* binding sites, although it is clearly absent from the center of *Shox2* binding peaks (Fig. 4E), suggesting that a set of *Shox2* binding enhancers is in a poised state. Given the association of *Shox2* occupancy with limb-specific DHS sites and enhancer marks, we sought to determine if the occupancy of *Shox2* can be used as a feature to isolate limb-specific enhancers. We exploited the vista enhancer database (Visel et al., 2007) and found that only 19% of active enhancers validated through transgenic enhancer assays contain limb-specific activity (Fig. 4F). After filtering the active enhancers using *Shox2* occupancy as a criterion, the percentage of the limb-specific active enhancers increased to 50%. Consistent with *Shox2* expression in the developing proximal limb, many of the enhancers occupied by *Shox2* displayed proximal specific activity in the limb, as exemplified in Fig. 4G. These observations indicate that the enhancers occupied by *Shox2* and located near genes

involved in skeletogenesis integrate the transcriptional program specifically required for stylopod formation.

Genome-wide co-occupancy of Shox2 and Hox-TALE factors on candidate enhancers of osteogenic genes

We next sought to search for transcription co-factors of *Shox2* that co-operate in and underlie its unique function in stylopodial skeletogenesis. We first performed *de novo* motif discovery on *Shox2* binding peaks in the embryonic limb. As shown in Fig. 5, in contrast to results discovered using the same methods in hindlimb ChIP-Seq top peaks of Pitx1 (Infante et al., 2013), which is also a paired-like homeodomain transcription factor, the top motifs discovered in the *Shox2* binding sites are highly related to motifs for Hox-TALE factors, including those similar to the Hox9-TALE motif (Huang et al., 2012), Meis motif and Pbx-TALE motif. These analyses suggest an association of *Shox2* with Hox-TALE factors.

Given that Hox9, Pbx and Meis are all transcription factors that are highly abundant in the proximal limb (Capellini et al., 2011; Zakany and Duboule, 2007) and act potentially as determinants for accessible chromatin landscape, the outcome of the motif discovery on *Shox2*-occupied sites may be biased by the availability of transcription factor-accessible sites that are already established by Hox9, Pbx and Meis. To determine the specific association of *Shox2* with Hox-TALE factors, we further conducted *Shox2* ChIP-Seq on the developing palate where *Shox2* is specifically expressed in the anterior domain overlapping with the future bony hard palate (Gu et al., 2008; Yu et al., 2005) and performed motif discovery similarly. The occupancy of *Shox2* in the palate shows distal enhancer binding properties and high relevance to skeletogenesis similar to that in limb (Fig. 6A,B). TALE-related motifs were also discovered in the *Shox2*-bound peaks in the palate (Fig. 5). However, despite the similar association of *Shox2* with TALE-Hox factors in the limb and palate, the top peak signals of the limb and palate do not overlap (Fig. 6C), suggesting that *Shox2*, along with TALE-Hox factors, is involved in different sets of machineries for skeletogenesis in the embryonic limb and palate, respectively.

To understand the collaborative regulatory manner of *Shox2* and Hox-TALE, we performed ChIP-Seq of Pbx, a key TALE family homeodomain factor, using E12.5 limb tissue. The top motifs discovered from the Pbx-occupied sites (Fig. 5) are similar to that discovered from the *Shox2*-occupied sites, and GO analysis indicates a similar function for Pbx in controlling cis-regulatory modules near skeletogenic genes in the developing limb (Fig. 6D,E). Furthermore, the motif for Meis was abundant in the peak center of Pbx ChIP-Seq data, consistent with the fact that Pbx and Meis often exist in the same transcription complex and share the same binding sites (Choe et al., 2009; Moens and Selleri, 2006). Interestingly, a discrepant genome-wide binding pattern between Pbx in the limb and that of Pbx and Meis in the brachial arches (BAs) (Amin et al., 2015) was also discovered (Fig. 6F), indicating that Pbx, similar to *Shox2*, is involved in a set of transcription programs unique for the skeletal patterning of the limb. A unique genome-wide co-occupation between *Shox2* and Pbx was further revealed by heat-map plotting (Fig. 6G) with the binding signals of Hand2 (Osterwalder et al., 2014) and Runx2 (Wu et al., 2014), which are crucial for skeletal formation. Moreover, aggregate plots (Fig. 6H) indicate that the binding peaks of *Shox2* colocalize with those of Pbx in the embryonic limb (this study) and Meis (Amin et al., 2015), suggesting that *Shox2* and TALE factors can function in the same transcription complex.

Interaction of *Shox2* and Pbx binding peaks resulted in about 9000 co-occupied elements that cluster around skeletogenic-




Fig. 4. Shox2 predominantly binds to limb-specific distal-acting enhancers involved in skeletogenesis. (A) Immunoprecipitation after crosslinking shows efficiency and specific pull down of Shox2 from E12.5 *Shox2*^{HA/+} limbs after crosslinking. (B) GO analysis on gene list associated with Shox2 binding sites shows specific association of Shox2 occupancy with skeletogenic-related genes. (C) The majority of Shox2 binding peaks have great distance to its nearest transcription starting sites (TSS) (top panel), and aggregate plots based on average phastcons across vertebrates indicate that the majority of these sites are highly conserved (bottom panel). (D) Heat-map plot of Shox2 occupancy signals at E12.5 and E13.5 in relation to accessible chromatin landscape assessed by DNase I hypersensitivity sequencing (DHS) of E11.5 embryonic limb, and postnatal heart and lung. (E) Aggregate plots on binding signals of H3K4me1, H3K27ac and H3K27me3 in embryonic limb at E11.5 around summits of Shox2 binding sites. (F) Pie graph shows the percentage of enhancers with limb activities in total (top panel) and Shox2-occupied (bottom panel) enhancers verified by vista enhancer projects. (G) Representative transgenic embryos showing proximal (P) limb activity of enhancers harboring Shox2-occupied sites. In the right-hand panel, a genome browser view shows a prominent Shox2 binding site (orthologs to HS774) in the intron of *Zfx4* along with H3K27ac ChIP signal obtained in embryonic limb.

related genes (Fig. 6I). Moreover, multiple Shox2 and Pbx co-occupied sites were found around such genes, for example, flanking *Tbx18* and *Runx2* (Fig. 6J), suggesting that these putative regulatory elements function additively on their putative target gene as a ‘regulatory archipelago’ – a phenomenon that was found for the regulation of *Hox* genes (Montavon et al., 2011). Remarkably, within the cluster of Shox2-Pbx co-occupied

enhancers downstream of *Runx2*, an enhancer that is located within the same topologically associated domain (TAD) as *Runx2* [inferred from published Hi-C data (Dixon et al., 2012)] showed proximal limb specific activity in the transgenic enhancer assay (Fig. 6K). This observation suggests that the regional control of *Runx2* expression by a Shox2-TALE-Hox mechanism contributes to stylopodial skeleton patterning.




Fig. 5. TALEfactor-related motifs are enriched in *Shox2*-binding sites. Top motifs discovered in the binding sites of *Shox2* (limb and palate), *Pbx* (limb), *Shox2/Pbx* co-occupied sites (limb) and *Pitx1* binding sites (limb).

***Shox2* exhibits a complementary expression gradient with and represses the expression of TALE factors in the stylopod**

Given a strict requirement of *Shox2* for *Runx2* expression in the stylopod and the co-occupancy of *Shox2* and *Pbx* on the regulatory elements of *Runx2*, we initially hypothesized that *Shox2* and TALE-Hox factors would be collectively required for the expression of key genes for stylopod patterning. This notion seemed to be supported by the hypothesis that *Meis* and *Pbx* genes are essential for stylopodial skeleton patterning based on their strong proximal limb expression (Capellini et al., 2011; Tabin and Wolpert, 2007). To determine if an epistatic additive output of *Shox2* and TALE factors contributes to stylopod patterning, we first analyzed the *Shox2*⁺ domain in relation to that of *Meis* gene expression. As shown in Fig. 7A-C, similar to previous reports (Mercader et al., 2000), *Meis1/2* is expressed most strongly in the proximal limb adjacent to the trunk, and the expression intensity decreases distally. To our surprise, the expression domain of *Meis1/2* appears partially overlapped with, but complementary to the *Shox2*⁺ domain that increases distally in the stylopod (Fig. 7A-C). A closer examination on the expression of *Meis* and *Pbx* proteins and *Shox2* in the developing stylopod also identified a partial exclusive expression of both *Meis* and *Pbx* proteins from *Shox2*-expressing cells surrounding the cartilage primordium (Fig. 7D-K). These observations together suggest that the *Shox2*⁺ perichondrial mesenchymal cells acquire a distinct distal identity within the stylopod, and *Shox2* may enforce this identity by repressing the expression of TALE transcription factors. Consistently, *Shox2* colocalizes with both *Pbx* and *Meis* transcriptional regulators on putative cis-regulatory elements near *Meis* and *Pbx* genes (Fig. S4), suggesting that *Shox2* exerts its repressive function on *Meis* and *Pbx* via a self-regulatory machinery.

To further understand the epigenomic change underlying the unique identity of *Shox2*⁺ perichondrial mesenchymal cells, we compared the *Pbx/Meis* ChIP-Seq data obtained from embryonic trunk (Penkov et al., 2013) with our *Shox2/Pbx* ChIP-Seq data. As summarized in the Venn diagram (Fig. 7L), the *Shox2/Pbx* binding sites in the limb overlap very little with the *Pbx/Meis* binding sites in the trunk, consistent with the notion that the *Shox2*⁺ perichondrial cells have a distinct chromatin landscape accessible to TALE factors.

The cis-regulatory elements for *Meis* genes have not been characterized *in vivo*. Although *Meis1/2* are expressed in both the trunk and proximal limb, we reasoned that if the occupancy of *Shox2/TALE* transcription factors underlies the trunk to limb epigenomic change and that *Shox2* represses the expression of *Meis* and *Pbx* genes directly by acting on their putative enhancers, then the strong co-occupancy of *Shox2* and *Pbx* in the limb and the weak occupancy of *Meis* and *Pbx* in the trunk would serve as a principle to identify limb-specific enhancers for *Meis*. As shown in Fig. 7M, a potential enhancer for *Meis1* showed prominent co-occupancy of *Shox2* and *Pbx* in the limb, but mild occupancy by *Meis* and *Pbx* in the trunk. Transgenic enhancer assay confirmed its enhancer activity in the developing limb (Fig. 7N). Interestingly, this site does not show identifiable H3K27ac ChIP-Seq signal in the limb (Fig. S4) (Shen et al., 2012), suggesting that co-occupancy by context-specific transcription factors could serve as a more sensitive approach for identifying tissue-specific enhancers. In addition, this enhancer showed H3K27ac enrichment in differentiated osteoblast-like cell line (Fig. S4) (St John et al., 2014), suggesting that it is an osteogenic enhancer for *Meis1* and that *Shox2* represses this enhancer to prevent *Meis1* expression in perichondrial osteogenic




Fig. 6. Genome-wide co-occupancy of Shox2 with Hox-TALE factors on osteogenic genes. (A-F), ChIP-Seq of Shox2 on the developing palate (A-C) and ChIP-Seq of Pbx on the developing limb (D-F) at E12.5. GO analysis and distance to TSSs histogram of Shox2-Palate (A,B) and Pbx-Limb (D,E) show similar functional and binding properties to Shox2-Limb ChIP-Seq data. K-mean cluster based on binding signal shows distinct binding preference of Shox2 occupancy in the limb compared with that in the palate (C). Similarly, Pbx preferentially binds to sites that are relatively weakly occupied by Pbx and Meis in the developing brachial arch (BA) (F). (G) Heat-map plot of binding signals of Shox2 (limb), Pbx (limb), Hand2 (limb) and Runx2 (osteogenic cell line) around Shox2 binding sites in E12.5 limb. (H) Aggregate plots on ChIP binding signal of Shox2 (limb), Pbx (limb) and Meis (BA) around Shox2 binding sites. (I) Venn diagram shows the ~9000 co-binding sites of Shox2 and Pbx in proportion to the top ~34,000 Shox2 and Pbx binding sites in E12.5 limb. (J) Shox2 and Pbx co-occupied enhancers cluster around *Tbx18* and *Runx2* (highlighted by arrowheads). (K) Representative transgenic embryo of e1461, a putative enhancer for *Runx2* (indicated in J), shows proximal limb-specific activity (arrowheads).

lineage cells. In support of this notion, in the absence of *Shox2*, an elevated expression of Meis was observed in the distal region of the humerus (Fig. 7O), and elevated Meis and Pbx expression was also detected in the *Shox2*⁺ perichondrial mesenchymal cells (Fig. S5). *Shox2* appears to establish a trunk to limb transition status (Fig. 7P). It was reported previously that excessive expression of Pbx (Gordon et al., 2010) or Meis (Mercader et al., 2009) inhibited osteogenesis. *Shox2* thus probably functions to antagonize the inhibitory effect of Meis and Pbx for stylopodial skeletogenesis. This hypothesis is also in line with the fact that excessive proximal RA signaling that is

upstream of Meis could also cause failure of proper skeletogenesis in the developing limb, including the stylopod (Cunningham and Duester, 2015).

Shox2 functions as a dominant repressor in the mesenchyme of embryonic limb

The likely repressive function of *Shox2* on the expression of Meis and Pbx genes prompted us to further understand the general function of *Shox2* in transcriptional regulation of its putative target genes. We accordingly performed RNA-Seq to profile the




Fig. 7. *Shox2* exhibits an opposite expression gradient with and represses the expression of TALE factors in the stylopod. (A–C) Co-immunofluorescence of E12.5 *Shox2*^{Cre/+}; *Rosa*^{mTmG} limb shows opposite gradients of Meis expression and *Shox2*⁺ domains along the proximal (A) to distal (C) axis in the stylopodi. The cartilaginous domains are circled by dashed lines. (D–K) Co-immunofluorescence on cross sections of E12.5 *Shox2*^{HA/+} forelimb shows complementary expression of *Shox2* to that of Meis (D,E,H,I) and Pbx (F,G,J,K) in the stylopod. Note that the signals for both Meis and Pbx staining are stronger in the proximal domain (D–G) compared with that in distal domain (H–K). The cartilaginous domains are circled by dashed lines and the *Shox2*-expressing domain is highlighted by solid lines. (L) Venn diagram shows very little overlap of Pbx and Meis binding sites to the *Shox2*/Pbx co-occupied sites. (M,N) Binding signal of *Shox2*, Pbx (limb and trunk), Meis (BA and trunk) downstream of *Meis1*, the most prominent binding site with co-binding of *Shox2*, Pbx and Meis is indicated by arrowheads. The limb-specific enhancer activity (arrowheads) of this site, along with short flanking sequence (1013-bp) (chr11:18612148–18613160) was confirmed by transgenic enhancer assay (N). (O) Immunofluorescence on sections of E12.5 *Shox2*^{Cre/+}; *Rosa*^{mTmG} limb at the distal portion of the stylopod shows elevated expression of Meis (arrowheads) compared with that in littermate control *Shox2*^{Cre/+}; *Rosa*^{mTmG} embryos. (P) Schematic model shows that stylopodial skeleton primordium (SP) is developed in the juxtaposition of the most proximal trunk-limb transition domain, where TALE factors are present, and the relative distal *Shox2* dominant domain. Such identity is lost in the absence of *Shox2*. H, humerus; R, radius; U, ulna.

transcriptome of GFP⁺ cells sorted from E12.5 *Shox2*^{Cre/+}; *Rosa*^{mTmG} limb and compared results with those from *Shox2*^{Cre/+}; *Rosa*^{mTmG} mice. The list of differentially expressed genes (DEGs) was intersected to the list of genes with *Shox2*-bound peaks in their putative regulatory elements to identify *Shox2*-targeted genes. Subsequent analysis of the intersected DEGs and gene-peak association by BETA, a program designed for generalizing the function of transcription factors (Wang et al., 2013), showed that *Shox2* functions primarily as a repressor (Fig. 8A). Additionally, the same analysis using *Shox2*/Pbx co-bound peaks as input also revealed a repressive function for *Shox2* (data not shown),

suggesting that TALE-Hox machinery is also involved in the repressive action of *Shox2*. GO analysis further demonstrated that the putative *Shox2* repressed targets are more relevant to limb development compared with targets activated by *Shox2* (Fig. 8B). Indeed, many putative direct repressive targets of *Shox2*, such as *Prrx1*, *Osr2*, *Gria2*, *Epha7*, *Rsrc1* and *Bmp4* (Tables S1 and S2), were found to show elevated/ectopic expression in the absence of *Shox2* in our previous studies by microarray and *in situ* hybridization on E10.5 and E11.5 limbs (Vickerman et al., 2011; Yu et al., 2007). Similar to *Runx2* and *Tbx18* (Fig. 6J), *Shox2*-TALE co-occupied sites were also identified as clusters around their




Fig. 8. *Shox2* functions as a dominant repressor in the mesenchyme of embryonic limb. (A) Schematic and representative results for integrative interpretation of the general function of *Shox2*. (B) GO analysis for genes associated with *Shox2* occupancy that are upregulated (putative repressive targets) and that are downregulated (putative activate targets) in the absence of *Shox2*. (C) Binding signal of *Shox2*, *Pbx* (limb), *Meis* (BA) downstream of *Bmp4*, the co-binding sites of *Shox2*, *Pbx* and *Meis* are indicated by arrowheads. The 2237 bp fragment (chr14:46840958–46843194) containing this binding sites was characterized by transgenic enhancer assay and a representative transgenic embryo is shown next to real-time *Shox2* expression at the same stage. (D) Binding signal of *Shox2*, *Pbx* (limb), *Meis* (BA) around the *Shox2-Rsrc1* locus with two characterized enhancers indicated (LHB-A, m741 and its human ortholog hs741). (E) In the absence of *Shox2* in the embryonic limb (*mm741-lacZ*; *Prrx1-Cre*; *Shox2^{+/F}*), the β -galactosidase activity driven by the *Rsrc1* enhancer (m741) is elevated. (F) Normalized luciferase activity of co-transfection luciferase assay in C3H10T1/2 cells shows direct repressive activity of *Shox2* on the LHB-A enhancer.

associated genes (Fig. S4), supporting the notion of a convergent function of *Shox2*-Hox-TALE machinery toward their target genes.

We next investigated whether *Shox2* represses target enhancers directly by using a transgenic enhancer assay. First, we used an enhancer containing a *Shox2*-*Pbx*-*Meis* co-occupied element downstream of *Bmp4*, which revealed complementary activity of the transgenic enhancer compared with the expression domains of *Shox2* in developing limbs (Fig. 8C), suggesting a repressive role of *Shox2* on this enhancer. We next created a stable transgenic line (*mm741-lacZ*) from a *Shox2*-*Pbx*-*Meis* co-bound enhancer in intron 3 of the *Rsrc1* in the *Rsrc1-Shox2* locus (Fig. 8D), given that *Rsrc1* is a robust repressive target of *Shox2* and that *Shox2* also shows self-repressive activity (Fig. S6). Similar to its human ortholog *hs741* (Fig. 5G), this enhancer displayed strong limb-specific activity (Fig. 8E). Compounding this transgenic enhancer-reporter allele to *Shox2^{-/-}* background caused significant elevation of the enhancer activity in the proximal limb (Fig. 8E; $N=3$). A direct repressive activity of *Shox2* toward the *Shox2-Rsrc1* locus is further supported by the co-occupancy of *Shox2*, *Pbx* and *Meis* on an enhancer of *Shox2* itself (Rosin et al., 2013) and a strong repressive activity of *Shox2* on this enhancer in luciferase reporter

assay *in vitro* (Fig. 8F). Interestingly, many genes we identified as putative repressive targets of *Shox2* were shown or known previously to be broadly expressed in mesenchymal progenitor cells of the early developing limb (Vickerman et al., 2011; Yu et al., 2007) and less widely expressed in the osteogenic lineage, raising the possibility that the repressive action of *Shox2* helps to steer the progenitor cells away from a non-osteogenic cell fate.

DISCUSSION

A *Shox2*-coordinated transcription program for stylopod patterning

In this study, we identified a *Shox2⁺* cell population specifically required for the patterning of the stylopodial skeleton, as summarized in Fig. 9. This population of *Shox2⁺* perichondrial mesenchymal cells appears to instruct the maturation and hypertrophic differentiation of chondrocytes in the cartilaginous mode and contributes to the osteogenic lineage at later stage, because in the *Shox2^{-/-}* limb, the stylopodial cartilage mode fails to undergo hypertrophy and lacks bone formation (Cobb et al., 2006; Yu et al., 2007), in contrast to the milder limb phenotype in mice carrying cartilage-specific inactivation of *Shox2* (Bobick and Cobb,




Fig. 9. A *Shox2*-coordinated transcription program for stylopod patterning. In the developing proximal limb, juxtaposition of the proximal TALE-dominant domain and the relative distal *Shox2*-dominant domain (where *Shox2* is the dominant identity and the dominant form of *Shox2*/TALE co-occupancy on their co-occupied enhancers) results in transcription that is favorable for osteogenesis of the perichondrial *Shox2*⁺ progenitor cells. These cells simultaneously instruct the chondrogenic differentiation of stylopod skeleton primordia (SP) and undergo osteogenic differentiation to provide osteoblasts to form bone.

2012; and this study). In the perichondrial mesenchymal cells, *Shox2* acts to determine the fate of osteogenic lineage, as it is required for the expression of key osteogenic genes including *Runx2*. On the other hand, *Shox2* represses a panel of genes, as demonstrated by integrated analysis of our RNA-Seq and ChIP-Seq data. Among the repressed genes are *Meis* and *Pbx*, both of which contribute to correct proximal skeleton patterning. Together with the fact that *Shox2*, *Meis* and *Pbx* show broad genome-wide co-occupation on osteogenic genes, the repressive activity of *Shox2* toward *Meis* and *Pbx* assists to establish a *Shox2* dominant form of *Shox2*/TALE occupancy on *Shox2*/TALE co-occupied regulatory elements and favors pro-osteogenic transcription output essential for the instructive role of the perichondrial cells towards cartilaginous mode patterning as well as osteogenic cell fate (Fig. 9).

Enhancer grammar for proximal limb patterning and epigenomic specification of the proximal limb

Understanding the grammar for tissue-specific enhancers is essential for deciphering the subregion-specific transcription output. In addition to the limb enhancers characterized by approaches utilizing whole-limb tissue (Visel et al., 2009), the enhancers for the zone of polarizing activity (ZPA) and apical ectodermal ridge (AER) were also characterized by microdissection with H3K27ac ChIP-Seq (VanderMeer et al., 2014). However, the enhancer grammar underlying the PD patterning of the limb and whether the PD specificity can be recapitulated by enhancer elements are yet to be addressed. We took the advantage of the specific expression domain of *Shox2* in the proximal limb and its essential function for proximal limb patterning to characterize putative functional enhancers with proximal limb-specific activities. By computational and comparative analyses on our *Shox2* ChIP-Seq data obtained from the limb and palate as well as *Pbx* ChIP-Seq on the limb with existing ChIP-Seq data, we found that the regulatory elements for *Shox2*/TALE co-occupation probably represent the key features for the proximal limb-specific enhancers. This notion is further supported by a *de novo* discovered proximal limb enhancer for *Meis1* (*Meis1*^{En}) based on *Shox2*/TALE co-occupancy.

Although *Meis* and *Pbx* are strongly expressed in the trunk region (Mercader et al., 2000; Penkov et al., 2013) and our study also revealed an expression gradient of *Meis* from the trunk to the distal end of the stylopod, the *Meis1*^{En} identified in this study is weakly occupied by *Meis* and *Pbx* in the trunk region (Penkov et al., 2013), suggesting that the alternative use of the limb enhancer that is repressed by *Shox2* underlies the trunk to limb (proximal to distal) expression gradient of *Meis*. Notably, a large population of *Shox2*/*Pbx* co-occupied sites is not (or is only weakly) accessible to *Pbx* and *Meis* in the trunk region (Fig. 7L), suggesting that the *Shox2*/TALE co-occupied elements that are specifically accessible in the limb represent the epigenomic change required for the specification of the proximal limb mesenchyme. This highlights the importance of *Shox2* in specification of the stylopod that emerges in juxtaposition of the trunk, with its strong *Meis*/*Pbx* expression and the proximal limb, where *Shox2* is highly expressed. However, because of the closely located binding centers of *Shox2* and *Pbx* genome wide (Fig. S7), and the lack of a *Pbx de novo* motif – a phenomenon that is typical for cooperative binding of transcription factors (Jolma et al., 2015) – *Shox2*-TALE co-occupancy appears to be competitive. Moreover, since *Hox9*/*Hox10* proteins were thought to interact with *Meis*/*Pbx* to pattern the proximal limb (Capellini et al., 2011; Zakany and Duboule, 2007), the fact that *Shox2* interacted directly with *Hoxa9* in co-IP assay (Fig. S8) further suggests that on the *Shox2*/TALE co-occupied enhancers, *Shox2* may also act as an alternative co-factor for *Hox9*/*Hox10* to exert a different transcription output. Interestingly, in the palate that is derived from the *Hox*-free first BA (Amin et al., 2015), *Shox2* displays a distinct pattern of genome-wide occupancy, implying that, in the absence of *Hox* factors, *Shox2*-TALE factors regulate a unique set of palate-specific modules.

Interestingly, a large population of *Shox2*/TALE co-occupied sites is also occupied by *Gli3* (Vokes et al., 2008), an early anterior-posterior limb patterning factor and an effector for *Shh* signaling, in the developing limb bud (Fig. S9). In light of the fact that *Hox* and *Shh* show substantial epistatic cross talks and that *Gli3* is essential for proximal limb skeleton development (Barna et al., 2005), the co-occupation of *Gli3* and *Shox2*/TALE suggests

that such cross talk is realized by converged transcription output on the same enhancers.

Cell lineages that are commissioned for patterning

The fact that *Shox2* mutation results in a specific ablation of the perichondrial *Shox2*^{+/+}*Runx2*⁺ osteogenic precursors and subsequently mispatterned cartilaginous mode in the stylopod highlight a crucial role for osteogenic precursors in chondrogenic differentiation. This conclusion is supported by phenotypic reminiscence in mice carrying *Shox2* inactivation in the osteogenic lineage. Notably, the expression of *Shox2* in many connective tissue cell types and its later expression in perichondrial outer layer cells are reminiscent of that of *Hox11* (Swinehart et al., 2013), which patterns the zeugopodial skeleton elements. Together with the fact that the perichondrial expression of *Hox13* was also proposed to pattern the autopodial skeleton (Villavicencio-Lorini et al., 2010), our study indicates that the patterning can be exerted by controlling the specification and differentiation of the perichondrial osteogenic precursor cells to simultaneously modulate the patterning of cartilaginous mode and bone formation. Interestingly, in the *HoxA/D* compound mutant, the expression of *Shox2* in the embryonic perichondrium, but not chondrocytes, is severely affected (Neufeld et al., 2014), indicating that *Shox2* itself is a key effector for Hox-TALE patterning system in the stylopod and further supports the idea that Hox-TALE patterns skeletal elements by commissioning perichondrial cells. Given the instructive role of perichondrial cells on chondrocyte differentiation and maturation (Ohbayashi et al., 2002), further dissection of *Shox2*-specific targets in the osteogenic lineage would further highlight key factors involved in such patterning function.

MATERIALS AND METHODS

Mouse models

The *Shox2*^{HA}, *Shox2*^{+/-}, *Shox2*^{LacZ}, *Shox2*^{Cre}, *Shox2*^{Flox}, *Rosa*^{mTmG}, *Nkx2-5*^{Flox}, *Col2a1-Cre* and *Col3.6-Cre* alleles used in this study were described previously (Cobb et al., 2006; Liu et al., 2004; Ovchinnikov et al., 2000; Sun et al., 2013; Wang et al., 2014; Ye et al., 2015b; Yu et al., 2005). The animal experiments in this study were approved by The Tulane University Institutional Animal Care and Use Committee. Transgenic animal work performed at the Lawrence Berkeley National Laboratory (LBL) was reviewed and approved by the LBL Animal Welfare and Research Committee. Transgenic mouse assays were performed in *Mus musculus* FVB strain mice. Sample sizes were selected empirically based on our previous experience of performing transgenic mouse assays for >2000 total putative enhancers. Mouse embryos were only excluded from further analysis if they did not carry the reporter transgene or if they were not at the correct developmental stage. As all transgenic mice were treated with identical experimental conditions, and as there were no groups of animals directly compared in this section of the study, randomization and experimenter blinding were unnecessary and not performed.

Collection of embryos, histology, immunohistochemistry and skeletal staining

Embryos from timed pregnant females were fixed in ice-cold 4% paraformaldehyde (PFA), embedded in paraffin, and sectioned at 8 µm for immunohistochemistry analyses. Antibodies used in the study are described in supplementary Materials and Methods. Alcian Blue/Alizarin Red skeletal staining was performed using established protocol, as described previously (Bobick and Cobb, 2012; Yu et al., 2007).

Immunoprecipitations and western blotting

Immunoprecipitation (IP), co-immunoprecipitation (Co-IP), chromatin-immunoprecipitation (ChIP) and western blotting were performed as described previously (Ye et al., 2015b). ChIP-Seq and associated analysis

are described in Supplemental Information. Antibodies used for ChIP and ChIP-Seq are described in supplementary Materials and Methods.

FACS, RNA extraction and RNA sequencing

The GFP⁺ proximal embryonic limbs were dissected out from E12.5 *Shox2*^{Cre/+}*Rosa*^{mTmG} and *Shox2*^{Cre/-}*Rosa*^{mTmG} embryos under a fluorescence dissecting scope and subjected to digestion by a cocktail of collagenase I, II and IV, followed by a brief trypsin treatment. Suspended cells were sorted based on GFP signal and subsequently subjected to RNA extraction and RNA sequencing. The associated analysis is described in supplementary Materials and Methods.

Statistical analysis

All experiments were repeated at least three times. Quantification results are presented as mean±s.d., and statistical analysis was conducted using Student's *t*-test. For qPCR, reactions for each sample were also performed in triplicate. *P*<0.05 was considered significant.

Acknowledgements

The LHB-A-Luc plasmid used in this study was kindly provided by Jessica Rosin currently at Seattle Children's hospital.

Competing interests

The authors declare no competing or financial interests.

Author contributions

W.Y. and Y.C. conceived the project. W.Y. and Y.S. performed most experiments, collected and analyzed data. W.Y. and Z.H. performed and analyzed ChIP-Seq results. W.Y. and Z.H. generated constructs for transgenic enhancer assay. Z.H. performed luciferase assay. J.X., A.L., B.B., N.R., and R.S. helped with x-gal staining, histological and skeletal preparation. S.A.-O., D.Y., L.Z., B.B., C.-L.C., J.C., and Y.Z. provided necessary reagents. M.O. and A.V. performed transgenic enhancer assay described in the manuscript. W.Y. prepared figures and wrote the manuscript. J.C., M.O., A.V. and Y.Z. provided insights and helped in manuscript editing. Y.C. conducted final revision and editing of the manuscript.

Funding

We acknowledge financial support by grants from the National Institutes of Health [R01DE017792 and R01DE024152 to Y.C.; R24HL123879, U01DE024427, R01HG003988, U54HG006997, and UM1HL098166 to A.V.], an American Heart Association Predoctoral Fellowship [13PRE1375003 to W.Y.], a grant [WKJ-FJ-24] from the National Health and Family Planning Commission of the People's Republic of China, and a grant [201510011] from the International Collaboration Program of Fujian Province, China. M.O. was supported by a Swiss National Science Foundation (Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung) Fellowship. Research conducted at the E.O. Lawrence Berkeley National Laboratory was performed under U.S. Department of Energy Contract DE-AC02-05CH11231, University of California. Deposited in PMC for release after 12 months.

Data availability

ChIP-Seq and RNA-Seq data have been deposited in Gene Expression Omnibus (GEO) with accession numbers GSE81897 and GSE82300, respectively. Available at: ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81897 and ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82300.

Supplementary information

Supplementary information available online at <http://dev.biologists.org/lookup/doi/10.1242/dev.138750.supplemental>

References

- Amin, S., Donaldson, I. J., Zannino, D. A., Hensman, J., Ratray, M., Losa, M., Spitz, F., Ladam, F., Sagerström, C. and Bobola, N. (2015). *Hoxa2* selectively enhances Meis binding to change a branchial arch ground state. *Dev. Cell* **32**, 265–277.
- Attanasio, C., Nord, A. S., Zhu, Y., Blow, M. J., Biddie, S. C., Mendenhall, E. M., Dixon, J., Wright, C., Hosseini, R., Akiyama, J. A. et al. (2014). Tissue-specific SMARCA4 binding at active and repressed regulatory elements during embryogenesis. *Genome Res.* **24**, 920–929.
- Barna, M., Pandolfi, P. P. and Niswander, L. (2005). Gli3 and Plzf cooperate in proximal limb patterning at early stages of limb development. *Nature* **436**, 277–281.
- Bobick, B. E. and Cobb, J. (2012). *Shox2* regulates progression through chondrogenesis in the mouse proximal limb. *J. Cell Sci.* **125**, 6071–6083.
- Capellini, T. D., Zappavigna, V. and Selleri, L. (2011). Pbx homeodomain proteins: TALEnted regulators of limb patterning and outgrowth. *Dev. Dyn.* **240**, 1063–1086.

- Choe, S.-K., Lu, P., Nakamura, M., Lee, J. and Sagerström, C. G. (2009). Meis cofactors control HDAC and CBP accessibility at Hox-regulated promoters during zebrafish embryogenesis. *Dev. Cell* **17**, 561–567.
- Cobb, J., Dierich, A., Huss-Garcia, Y. and Duboule, D. (2006). A mouse model for human short-stature syndromes identifies Shox2 as an upstream regulator of Runx2 during long-bone development. *Proc. Natl. Acad. Sci. USA* **103**, 4511–4515.
- Colnot, C., Lu, C., Hu, D. and Helms, J. A. (2004). Distinguishing the contributions of the perichondrium, cartilage, and vascular endothelium to skeletal development. *Dev. Biol.* **269**, 55–69.
- Crocker, J., Abe, N., Rinaldi, L., McGregor, A. P., Frankel, N., Wang, S., Alsawadi, A., Valenti, P., Plaza, S., Payre, F. et al. (2015). Low affinity binding site clusters confer hox specificity and regulatory robustness. *Cell* **160**, 191–203.
- Cunningham, T. J. and Duester, G. (2015). Mechanisms of retinoic acid signalling and its roles in organ and limb development. *Nat. Rev. Mol. Cell Biol.* **16**, 110–123.
- Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S. and Ren, B. (2012). Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature* **485**, 376–380.
- Espinoza-Lewis, R. A., Yu, L., He, F., Liu, H., Tang, R., Shi, J., Sun, X., Martin, J. F., Wang, D., Yang, J. et al. (2009). Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2-5. *Dev. Biol.* **327**, 376–385.
- Gordon, J. A. R., Hassan, M. Q., Saini, S., Montecino, M., van Wijnen, A. J., Stein, G. S., Stein, J. L. and Lian, J. B. (2010). Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. *Mol. Cell. Biol.* **30**, 3531–3541.
- Gu, S., Wei, N., Yu, X., Jiang, Y., Fei, J. and Chen, Y. (2008). Mice with an anterior cleft of the palate survive neonatal lethality. *Dev. Dyn.* **237**, 1509–1516.
- Huang, Y., Sitwala, K., Bronstein, J., Sanders, D., Dandekar, M., Collins, C., Robertson, G., MacDonald, J., Cozard, T., Bilenky, M. et al. (2012). Identification and characterization of Hoxa9 binding sites in hematopoietic cells. *Blood* **119**, 388–398.
- Hudry, B., Thomas-Chollier, M., Volovik, Y., Duffraisse, M., Dard, A., Frank, D., Technau, U. and Merabet, S. (2014). Molecular insights into the origin of the Hox-TALE patterning system. *Elife* **3**, e01939.
- Infante, C. R., Park, S., Mihal, A. G., Kingsley, D. M. and Menke, D. B. (2013). Pitx1 broadly associates with limb enhancers and is enriched on hindlimb cis-regulatory elements. *Dev. Biol.* **374**, 234–244.
- Jolma, A., Yin, Y., Nitta, K. R., Dave, K., Popov, A., Taipale, M., Enge, M., Kivioja, T., Morgunova, E. and Taipale, J. (2015). DNA-dependent formation of transcription factor pairs alters their binding specificity. *Nature* **527**, 384–388.
- Kmita, M., Tarchini, B., Zakany, J., Logan, M., Tabin, C. J. and Duboule, D. (2005). Early developmental arrest of mammalian limbs lacking HoxA/HoxD gene function. *Nature* **435**, 1113–1116.
- Kondrashov, N., Pusic, A., Stumpf, C. R., Shimizu, K., Hsieh, A. C., Xue, S., Ishijima, J., Shiroishi, T. and Barna, M. (2011). Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. *Cell* **145**, 383–397.
- Liu, F., Woitge, H. W., Braut, A., Kronenberg, M. S., Lichter, A. C., Mina, M. and Kream, B. E. (2004). Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. *Int. J. Dev. Biol.* **48**, 645–653.
- Long, F. and Ornitz, D. M. (2013). Development of the endochondral skeleton. *Cold Spring Harb. Perspect. Biol.* **5**, a008334.
- Mann, R. S., Lelli, K. M. and Joshi, R. (2009). Hox specificity: unique roles for cofactors and collaborators. *Curr. Top. Dev. Biol.* **88**, 63–101.
- Mercader, N., Leonardo, E., Piedra, M. E., Martinez, A. C., Ros, M. A. and Torres, M. (2000). Opposing RA and FGF signals control proximodistal vertebrate limb development through regulation of Meis genes. *Development* **127**, 3961–3970.
- Mercader, N., Salleri, L., Criado, L. M., Pallares, P., Parras, C., Cleary, M. L. and Torres, M. (2009). Ectopic Meis1 expression in the mouse limb bud alters P-D patterning in a Pbx1-independent manner. *Int. J. Dev. Biol.* **53**, 1483–1494.
- Moens, C. B. and Selleri, L. (2006). Hox cofactors in vertebrate development. *Dev. Biol.* **291**, 193–206.
- Montavon, T., Soshnikova, N., Mascres, B., Joye, E., Thevenet, L., Splinter, E., de Laat, W., Spitz, F. and Duboule, D. (2011). A regulatory archipelago controls Hox genes transcription in digits. *Cell* **147**, 1132–1145.
- Neufeld, S. J., Wang, F. and Cobb, J. (2014). Genetic interactions between Shox2 and Hox genes during the regional growth and development of the mouse limb. *Genetics* **198**, 1117–1126.
- Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N. and Takada, S. (2002). FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. *Genes Dev.* **16**, 870–879.
- Osterwalder, M., Speziale, D., Shoukry, M., Mohan, R., Ivanek, R., Kohler, M., Beisel, C., Wen, X., Scales, S. J., Christoffels, V. M. et al. (2014). HAND2 targets define a network of transcriptional regulators that compartmentalize the early limb bud mesenchyme. *Dev. Cell* **31**, 345–357.
- Ovchinnikov, D. A., Deng, J. M., Ogunrinu, G. and Behringer, R. R. (2000). Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. *Genesis* **26**, 145–146.
- Parker, H. J., Piccinelli, P., Sauka-Spengler, T., Bronner, M. and Elgar, G. (2011). Ancient Pbx-Hox signatures define hundreds of vertebrate developmental enhancers. *BMC Genomics* **12**, 637.
- Pearson, J. C., Lemons, D. and McGinnis, W. (2005). Modulating Hox gene functions during animal body patterning. *Nat. Rev. Genet.* **6**, 893–904.
- Penkov, D., Mateos San Martin, D., Fernandez-Diaz, L. C., Rossello, C. A., Torroja, C., Sanchez-Cabo, F., Warnatz, H. J., Sultan, M., Yaspo, M. L., Gabrieli, A. et al. (2013). Analysis of the DNA-binding profile and function of TALE homeoproteins reveals their specialization and specific interactions with Hox genes/proteins. *Cell Rep.* **3**, 1321–1333.
- Raines, A. M., Magella, B., Adam, M. and Potter, S. S. (2015). Key pathways regulated by HoxA9,10,11/HoxD9,10,11 during limb development. *BMC Dev. Biol.* **15**, 28.
- Rosin, J. M., Abassah-Oppong, S. and Cobb, J. (2013). Comparative transgenic analysis of enhancers from the human SHOX and mouse Shox2 genomic regions. *Hum. Mol. Genet.* **22**, 3063–3076.
- Shen, Y., Yue, F., McCleary, D. F., Ye, Z., Edsall, L., Kuan, S., Wagner, U., Dixon, J., Lee, L., Lobanov, V. V. et al. (2012). A map of the cis-regulatory sequences in the mouse genome. *Nature* **488**, 116–120.
- Slattery, M., Riley, T., Liu, P., Abe, N., Gomez-Alcala, P., Dror, I., Zhou, T., Rohs, R., Honig, B., Bussemaker, H. J. et al. (2011). Cofactor binding evokes latent differences in DNA binding specificity between Hox proteins. *Cell* **147**, 1270–1282.
- St John, H. C., Bishop, K. A., Meyer, M. B., Benkuský, N. A., Leng, N., Kendzierski, C., Bonewald, L. F. and Pike, J. W. (2014). The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone. *Mol. Endocrinol.* **28**, 1150–1165.
- Sun, C., Zhang, T., Liu, C., Gu, S. and Chen, Y. (2013). Generation of Shox2-Cre allele for tissue specific manipulation of genes in the developing heart, palate, and limb. *Genesis* **51**, 515–522.
- Swinehart, I. T., Schlientz, A. J., Quintanilla, C. A., Mortlock, D. P. and Wellik, D. M. (2013). Hox11 genes are required for regional patterning and integration of muscle, tendon and bone. *Development* **140**, 4574–4582.
- Tabin, C. and Wolpert, L. (2007). Rethinking the proximodistal axis of the vertebrate limb in the molecular era. *Genes Dev.* **21**, 1433–1442.
- VanderMeer, J. E., Smith, R. P., Jones, S. L. and Ahituv, N. (2014). Genome-wide identification of signaling center enhancers in the developing limb. *Development* **141**, 4194–4198.
- Vickerman, L., Neufeld, S. and Cobb, J. (2011). Shox2 function couples neural, muscular and skeletal development in the proximal forelimb. *Dev. Biol.* **350**, 323–336.
- Villavicencio-Lorini, P., Kuss, P., Friedrich, J., Haupt, J., Farooq, M., Turkmen, S., Duboule, D., Hecht, J. and Mundlos, S. (2010). Homeobox genes d11-d13 and a13 control mouse autopod cortical bone and joint formation. *J. Clin. Invest.* **120**, 1994–2004.
- Visel, A., Minovitsky, S., Dubchak, I. and Pennacchio, L. A. (2007). VISTA Enhancer Browser—a database of tissue-specific human enhancers. *Nucleic Acids Res.* **35**, D88–D92.
- Visel, A., Blow, M. J., Li, Z., Zhang, T., Akiyama, J. A., Holt, A., Plajzer-Frick, I., Shoukry, M., Wright, C., Chen, F. et al. (2009). ChIP-seq accurately predicts tissue-specific activity of enhancers. *Nature* **457**, 854–858.
- Vokes, S. A., Ji, H., Wong, W. H. and McMahon, A. P. (2008). A genome-scale analysis of the cis-regulatory circuitry underlying sonic hedgehog-mediated patterning of the mammalian limb. *Genes Dev.* **22**, 2651–2663.
- Wang, S., Sun, H., Ma, J., Zang, C., Wang, C., Wang, J., Tang, Q., Meyer, C. A., Zhang, Y. and Liu, X. S. (2013). Target analysis by integration of transcriptome and ChIP-seq data with BETA. *Nat. Protoc.* **8**, 2502–2515.
- Wang, J., Bai, Y., Li, N., Ye, W., Zhang, M., Greene, S. B., Tao, Y., Chen, Y., Wehrens, X. H. T. and Martin, J. F. (2014). Pitx2-microRNA pathway that delimits sinoatrial node development and inhibits predisposition to atrial fibrillation. *Proc. Natl. Acad. Sci. USA* **111**, 9181–9186.
- Wu, H., Whitfield, T. W., Gordon, J. A. R., Dobson, J. R., Tai, P. W. L., van Wijnen, A. J., Stein, J. L., Stein, G. S. and Lian, J. B. (2014). Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis. *Genome Biol.* **15**, R52.
- Ye, W., Song, Y., Huang, Z., Zhang, Y. and Chen, Y. (2015a). Genetic regulation of sinoatrial node development and pacemaker program in the venous pole. *J. Cardiovasc. Dev. Dis.* **2**, 282–298.
- Ye, W., Wang, J., Song, Y., Yu, D., Sun, C., Liu, C., Chen, F., Zhang, Y., Wang, F., Harvey, R. P. et al. (2015b). A common Shox2-Nkx2-5 antagonistic mechanism primes the pacemaker cell fate in the pulmonary vein myocardium and sinoatrial node. *Development* **142**, 2521–2532.
- Yu, L., Gu, S., Alappat, S., Song, Y., Yan, M., Zhang, X., Zhang, G., Jiang, Y., Zhang, Z., Zhang, Y. et al. (2005). Shox2-deficient mice exhibit a rare type of incomplete clefting of the secondary palate. *Development* **132**, 4397–4406.
- Yu, L., Liu, H., Yan, M., Yang, J., Long, F., Muneoka, K. and Chen, Y. (2007). Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. *Dev. Biol.* **306**, 549–559.
- Yue, F., Cheng, Y., Breschi, A., Vierstra, J., Wu, W., Ryba, T., Sandstrom, R., Ma, Z., Davis, C., Pope, B. D. et al. (2014). A comparative encyclopedia of DNA elements in the mouse genome. *Nature* **515**, 355–364.
- Zakany, J. and Duboule, D. (2007). The role of Hox genes during vertebrate limb development. *Curr. Opin. Genet. Dev.* **17**, 359–366.


SUPPLEMENTAL MATERIALS AND METHODS

List of primary antibodies for ChIP-Seq and Immunofluorescence. α -HA (Abcam, ab91110) (1:500 for immunofluorescence, 10 μ g per reaction for ChIP/ChIP-Seq), α -Runx2 (Abcam, ab76956) (1:500 for immunofluorescence), α -Sox9 (Abcam, 3C10) (1:500 for immunofluorescence), α -Meis (Santa Cruz, c-17) (1:500 for immunofluorescence), α -Pbx (Santa Cruz, C20) (1:500 for immunofluorescence, 10 μ g per reaction for ChIP/ChIP-Seq), α -GFP (ab13970) (1:5000 for immunofluorescence), α -Osx (Abcam, ab22552) (1:500 for immunofluorescence).


ChIP-Seq, transgenic enhancer assay, and RNA-Seq analysis. For ChIP-Seq, the list of libraries below, including controls, were generated [listed in the format of (antibody)-target-tissue-stage]: (α -HA)-Shox2-Limb-E12.5, (α -HA)-Shox2-Limb-E13.5, (α -HA)-Shox2-Palate-E12.5, (α -HA)-Shox2-Limb/Palate-E12.5, (α -Pbx)-Pbx-Limb-E12.5, Input (control), (α -HA)-Mixed Limb/Palate from *Shox2*^{+/+} mice-E12.5 (control). Peak calling was performed by MACS2 (Zhang et al., 2008) using default setting. The binding signals indicated and analyzed in the manuscript were generated by `-bdgcmp` (MACS2) to filter out background signal. The bedgraph generated was subsequently converted to bigwig (the format deposited in GEO) for easy of analysis and visualization. Motif discovery was performed using MEME suite (Ma et al., 2014) and RSAT (Medina-Rivera et al., 2015). GO analysis was performed using GREAT Input (McLean et al., 2010). Transgenic enhancer assay based on ChIP-Seq results, as described in the relevant figures was performed using established protocol (Visel et al., 2007). Additional analysis and handling peak files were performed using BEDtools in R. For RNA-Seq analysis, 3 sets of libraries were generated: whole limb (E12.5 WT), GFP⁺ (E12.5 *Shox2*^{Cre/+}; *Rosa*^{mTmG}) and GFP⁺ (E12.5 *Shox2*^{Cre/-}; *Rosa*^{mTmG}). RNA-Seq data were analyzed by Cufflink-Cuffdiff-CummRbund workflow (Trapnell et al., 2012). Additional methods not mentioned in details are available upon request.

Luciferase assay. Luciferase assay was performed similar to previously described (Yang et al., 2014). In brief, LHB-A-Luc (Rosin et al., 2013) and pCMV-LacZ plasmid were co-transfected with a mock (control) or a CMV-HA-Shox2-IRES-DsRed (Ye et al., 2015) in C3h10T1/2 cells. Cell lysis and subsequent measurement of luciferase activity in triplicate was performed as described (Yang et al., 2014).

SUPPLEMENTAL FIGURES




Supplemental Figure 1. Limited contribution of *Shox2*⁺ cells to zeugopodial osteogenesis and whole limb skeleton preparations of *Col2a1-Cre;Shox2*^{F/F} mice. (A) At E13.5, *Shox2* is expressed in the mesenchyme of the zeugopod (arrowheads) but is excluded from the perichondrial layer of the developing zeugopodial skeletal elements (arrows). (B) At E17.5, the *Shox2*⁺ cells can be found at dermal fibroblasts (arrowheads) but not osteogenic cells in the zeugopodial skeleton (arrows). (C) Skeleton preparations of P0 control and *Col2a1-Cre;Shox2*^{F/F} mice. R, radius; U, ulna.




Supplemental Figure 2. Representative qPCR verification of ChIP-Seq results. (A)


Locations of PCR amplicons (in mm9). (B) qPCR results in fold enrichment.




Supplemental Figure 3. GO analysis of each category of Shox2 binding sites. (A) Similar to that shown in Figure 4D, k-mean cluster and heatmap plotting of Shox2 occupancy signals at E12.5 and E13.5 in relation to accessible chromatin landscape assessed by Dnase I hypersensitivity sequencing (DHS) of E11.5 embryonic limb, and postnatal heart and lung. (B) GO analysis on each category of peaks determined by k-mean cluster.




Supplemental Figure 4. Example ChIP-Seq signal tracks around putative Shox2 target genes. (A) Binding signal of Shox2, Pbx (limb), Meis (BA), H3K27ac (E11.5 limb and osteogenic cell line) downstream of *Meis1*. Note that the site corresponding to *Meis^{En}* has weak signal of H3K27ac in the developing limb but strong H3K27ac in differentiated osteoblast-like cell line (arrow), suggesting that it is an osteogenic enhancer for *Meis1*. (B, C) Binding signal of Shox2 (limb), Pbx (limb, BA), Meis (BA) within the same TADs (delimited by Hi-C experiment) of Shox2 targeted genes including *Meis* (A), *Pbx* (A), *Prrx1* (C), *Bmp4* (C), *Gria2* (C), *Osr2* (C), and *Epha7* (C).




Supplemental Figure 5. *Shox2* represses the expression of TALE factors in the perichondrial mesenchyme. (A, B) In the absence of *Shox2*, the expression of Meis (A) and Pbx (B) is elevated in the perichondrial *Shox2*⁺ cells (arrowheads) in the *Shox2*^{Cre/-}; *Rosa*^{mTmG} mice at E12.5 (A) and E13.5 (B), respectively.




Supplemental Figure 6. *Shox2* represses its own expression. (A, B) In the absence of *Shox2*, the expression of *LacZ* regulated by the *Shox2* locus is elevated (B) compared to the littermate *Shox2*^{LacZ/+} control.



Supplemental Figure 7. Aggregate plot of Shox2 and Pbx binding signals on their co-occupied sites (~9000) shows their closely located peak centers.




Supplemental Figure 8. Co-immunoprecipitation (Co-IP) indicates direct interaction of Shox2 and Hoxa9. Co-transfection in HEK293 cells followed by co-IP indicates that Shox2 can directly interact with Hoxa9.



Supplemental Figure 9. Occupancy of Shox2 in the Gli3 occupied sites in the developing limb. Venn diagram shows a great portion of Gli3 (Vokes et al., 2008) occupied sites (1107/5274) that are simultaneously occupied by Shox2 and Pbx in the developing limb.

Supplemental Table 1. Lists of Shox2 directly repressed genes that are consistent across previously published microarray analysis (Vickerman et al., 2011) and RNA-Seq analysis in this study.

[Click here to Download Table S1](#)



SUPPLEMENTAL REFERENCES

- Ma, W., Noble, W. S. and Bailey, T. L.** (2014). Motif-based analysis of large nucleotide data sets using MEME-ChIP. *Nat Protoc* **9**, 1428-1450.
- McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., Wenger, A. M. and Bejerano, G.** (2010). GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**, 495-501.
- Medina-Rivera, A., Defrance, M., Sand, O., Herrmann, C., Castro-Mondragon, J. A., Delerce, J., Jaeger, S., Blanchet, C., Vincens, P., Caron, C., et al.** (2015). RSAT 2015: Regulatory Sequence Analysis Tools. *Nucleic Acids Res* **43**, W50-56.
- Rosin, J. M., Abassah-Oppong, S. and Cobb, J.** (2013). Comparative transgenic analysis of enhancers from the human SHOX and mouse Shox2 genomic regions. *Hum Mol Genet* **22**, 3063-3076.
- Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L. and Pachter, L.** (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* **7**, 562-578.
- Vickerman, L., Neufeld, S. and Cobb, J.** (2011). Shox2 function couples neural, muscular and skeletal development in the proximal forelimb. *Dev Biol* **350**, 323-336.
- Visel, A., Minovitsky, S., Dubchak, I. and Pennacchio, L. A.** (2007). VISTA Enhancer Browser--a database of tissue-specific human enhancers. *Nucleic Acids Res* **35**, D88-92.
- Vokes, S. A., Ji, H., Wong, W. H. and McMahon, A. P.** (2008). A genome-scale analysis of the cis-regulatory circuitry underlying sonic hedgehog-mediated patterning of the mammalian limb. *Genes Dev* **22**, 2651-2663.
- Yang, G., Yuan, G., Ye, W., Cho, K. W. and Chen, Y.** (2014). An atypical canonical bone morphogenetic protein (BMP) signaling pathway regulates Msh homeobox 1 (Msx1) expression during odontogenesis. *J Biol Chem* **289**, 31492-31502.
- Ye, W., Wang, J., Song, Y., Yu, D., Sun, C., Liu, C., Chen, F., Zhang, Y., Wang, F., Harvey, R. P., et al.** (2015). A common Shox2-Nkx2-5 antagonistic mechanism primes the pacemaker cell fate in the pulmonary vein myocardium and sinoatrial node. *Development* **142**, 2521-2532.
- Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al.** (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137.